CardioMEMS in a Busy Cardiology Practice: Less than Optimal Implementation of a Valuable Tool to Reduce Heart Failure Readmissions

Abstract EN

Introduction.

Congestive heart failure is a leading cause of cardiovascular morbidity and mortality that results in a significant financial burden on healthcare expenditure.

Though various strategies have been employed to reduce hospital readmissions, one valuable tool that remains greatly underutilized is the CardioMEMS (Abbott), a remote pulmonary artery pressure-monitoring system, which has been shown to help reduce heart failure rehospitalizations in the CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients) trial.

Methods.

ICD-9/ICD-10 codes for chronic heart failure were used to identify patients who presented with congestive heart failure.

Of this group, those eligible for CardioMEMS device placement, as based on the CHAMPION trial definition, were selected.

Subsequently, a retrospective review of the electronic medical records was completed.

All patients were on ACC/AHA guideline-directed medical therapy and had at least one hospital admission for NYHA class III symptoms.

Results.

473 patients met the inclusion criteria, of which, 85 patients were found to be eligible for implantation of CardioMEMS device based on the CHAMPION trial definition.

Only 18/85 patients received the device, roughly 21%, and the overall CardioMEMS implantation rate was only 4% (18/473) of the total cohort.

Conclusion.

Despite the benefits to patients and reducing healthcare expenditure, there has been a poor adaptation of this groundbreaking technology.

Our study revealed that 79% of eligible heart failure patients did not receive the device.

Therefore, efforts need to be undertaken to improve physician and patient education of the device to complement the current standard of care for congestive heart failure.